Clinical Trials Logo
NCT number NCT01584388
Study type Interventional
Source Massachusetts General Hospital
Status Completed
Phase Phase 1/Phase 2
Start date April 2012
Completion date January 2015

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.

Clinical Trial Description

This two-center trial will enroll at total of 30 patients with IgG4-RD. The two participating sites are the Massachusetts General Hospital (Boston, MA) and the Mayo Clinic (Rochester, MN). All patients will receive rituximab 1 gram intravenously times two doses, separated by approximately 15 days. The primary efficacy outcome - disease remission and successful completion of the glucocorticoid taper - will be assessed at six months. Patients will be followed on the protocol for an additional six months after measurement of the primary outcome.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

See also
Status Clinical Trial Phase
 Recruiting NCT01774513 - EUS-guided Procore-biopsy in Diagnosing Autoimmune Pancreatitis N/A
 Recruiting NCT01845467 - Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Phase 4
 Recruiting NCT02705638 - Treatment of IgG4-Related Disease With Revlimid and Rituximab Phase 1
 Withdrawn NCT02766842 - Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore) Phase 2
 Completed NCT00588367 - CT Pancreas Perfusion N/A